Goldman Sachs
IMUC

Goldman Sachs’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Goldman Sachs’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,630
Closed -$208K – 7154
2013
Q4 		$208K Buy
+5,630
New +$533K ﹤0.01% 5938

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs's IMUC Position: Q1 2018 in Review

Goldman Sachs sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2018, closing a stake of 24,166 shares — an estimated $8K sold.

Goldman Sachs first reported a position in IMUC in Q2 2013 and held it in 15 quarters. The position peaked at $938K in Q2 2013. 23 funds tracked by Wall St. Rank hold IMUC as of Q1 2018.

  • Goldman Sachs reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 24,166 ImmunoCellular Therapeutics, Ltd. shares in Q1 2018, an estimated $8K.
  • Goldman Sachs first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 15 quarters.
  • Goldman Sachs's ImmunoCellular Therapeutics, Ltd. position peaked at $938K in Q2 2013.
  • 23 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.